Trial Profile
A Multicenter Randomized Double Blind Study Examining the Efficacy and Safety of Denosumab in Combination With First Line Platinum-based Chemotherapy for Patients With Bone Metastasis Secondary to Metastatic Urothelial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Calcium; Carboplatin; Cisplatin; Gemcitabine; Vitamin D
- Indications Bladder cancer; Bone metastases; Renal cancer; Ureteral neoplasms; Urogenital cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms DENIM
- 22 Nov 2021 Status changed from active, no longer recruiting to completed.
- 25 Sep 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2021.
- 25 Sep 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.